Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

27.01.15	Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses (GlobeNewswire)
23.01.15	Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US (GlobeNewswire)
23.01.15	Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera (GlobeNewswire)
21.01.15	Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients (GlobeNewswire)
19.01.15	Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients (GlobeNewswire)
08.01.15	Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA (GlobeNewswire)
07.01.15	Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee (GlobeNewswire)
07.01.15	Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology (GlobeNewswire)
01.01.15	Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion (GlobeNewswire)
26.12.14	First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis (GlobeNewswire)
23.12.14	Alcon treatment Travatan® receives EU approval for pediatric glaucoma patients (GlobeNewswire)
16.12.14	Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder (GlobeNewswire)
12.12.14	Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS (GlobeNewswire)
12.12.14	Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin (GlobeNewswire)
08.12.14	Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis (GlobeNewswire)
08.12.14	Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML (GlobeNewswire)
08.12.14	Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® (GlobeNewswire)
06.12.14	Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia (GlobeNewswire)
02.12.14	Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014 (GlobeNewswire)
01.12.14	Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) (GlobeNewswire)
28.11.14	Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1] (GlobeNewswire)
25.11.14	Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589 (GlobeNewswire)
24.11.14	Novartis drug Signifor® approved in EU, marking an advance for patients with inadequately controlled acromegaly (GlobeNewswire)
21.11.14	Novartis Foundation symposium showcases sustainable healthcare interventions (GlobeNewswire)
21.11.14	Novartis Stiftung präsentiert an ihrem Symposium nachhaltige Gesundheitsinterventionen (GlobeNewswire)
21.11.14	Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients (GlobeNewswire)
17.11.14	Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2] (GlobeNewswire)
16.11.14	Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients (GlobeNewswire)
15.11.14	Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients (GlobeNewswire)
12.11.14	Novartis und Malaria No More helfen Sambia das Behandlungsziel für Malaria zu erreichen, indem sie durch Power of One drei Millionen Behandlungseinheiten finanzieren (GlobeNewswire)
12.11.14	Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One (GlobeNewswire)
10.11.14	Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 (GlobeNewswire)
06.11.14	Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589 (GlobeNewswire)
28.10.14	Novartis erzielt im dritten Quartal ein solides Umsatzwachstum mit starken Margenverbesserungen und bedeutenden Innovationen (GlobeNewswire)
28.10.14	Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter (GlobeNewswire)
26.10.14	Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million (GlobeNewswire)
23.10.14	Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine (GlobeNewswire)
20.10.14	Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis (GlobeNewswire)
15.10.14	Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL) (GlobeNewswire)
10.10.14	Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patients (GlobeNewswire)
09.10.14	New data on the global economic impact and burden of preventable blindness and vision impairment highlighted for World Sight Day (GlobeNewswire)
08.10.14	Changes to the Novartis Executive Committee after expected completion of portfolio transactions (GlobeNewswire)
06.10.14	Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC (GlobeNewswire)
01.10.14	Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014 (GlobeNewswire)
27.09.14	Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC (GlobeNewswire)
27.09.14	Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial (GlobeNewswire)
26.09.14	Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly (GlobeNewswire)
25.09.14	Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis (GlobeNewswire)
17.09.14	Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014 (GlobeNewswire)
13.09.14	Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Börse New York in Grün: So steht der NASDAQ 100 aktuell
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter